Expert Opinion on Investigational Drugs

Article	Citations
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, safety, tolerability, and immunogenicity profiles of biosimilar candidate AVT03 (70 mg/mL	113
Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy	86
Theranostic strategies in sarcoma: preliminary clinical evidence	55
A randomized, Phase I study of the safety, tolerability, and pharmacokinetics of BI 764198, a transient receptor potential channel 6 (TRPC6) inhibitor, in healthy Japanese men	54
Investigational agents targeting alarmins for asthma treatment: insights and progress from phase I and II trials	46
Current status and perspective of immunotherapy for head and neck squamous cell carcinoma	44
Endoglin-targeted cancer therapies: current status and opportunities	41
Safety, pharmacokinetics, and efficacy of HY-072808 ointment, a novel PDE4 inhibitor, in adolescent and adult patients with mild-to-moderate AD	38
SGLT2 inhibitors: an evidence-based update on cardiovascular implications	35
New investigational drugs to treat Sjogren's syndrome: lessons learnt from immunology	35
Experimental drugs for erosive esophagitis: what is in the clinical development pipeline?	30
Ataxia-telangiectasia clinical trial landscape and the obstacles to overcome	29
Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies	29
Management of inflammaging in kidney diseases: focusing on the current investigational drugs	29
An overview of KRAS-targeting therapies for colorectal cancer in phase I and II development	28
Experimental drugs in clinical trials for COPD: artificial intelligence via machine learning approach to predict the successful advance from early-stage development to approval	27
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis	26
Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis	25
The role of 5-HT modulation in opioid withdrawal and neonatal opioid withdrawal syndrome: mechanisms and potential serotonergic targets	25
The role of extracellular vesicles in immune cell exhaustion and resistance to immunotherapy	25
Novel precision therapies for cholangiocarcinoma: an overview of clinical trials	25
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development	24
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of a biosimilar of denosumab (LY06006): a randomized, double-blind, single-dose, parallel-controlled clinical study in healthy Chinese su	24
CD200AR-L: mechanism of action and preclinical and clinical insights for treating high-grade brain tumors	24
Kallikrein inhibitors for angioedema: the progress of preclinical and early phase studies	23

Mass balance and absolute bioavailability of avenciguat ( 14 C) after intravenous or oral administration in healthy male participants	23
Endothelin receptor antagonists for diabetic kidney disease: back to the future?	22
Investigational new drug approval of DA-1241: what we know about GPR119 targeting for MASH therapy?	22
Odronextamab: a bispecific antibody for follicular lymphoma	21
Potassium channel modulators and schizophrenia: an overview of investigational drugs	20
Metformin: evidence from preclinical and clinical studies for potential novel applications in cardiovascular disease	20
Investigational drugs for the treatment of dysmenorrhea	20
IgA nephropathy: an overview of drug treatments in clinical trials	19
Duchenne muscular dystrophy: promising early-stage clinical trials to watch	19
Investigational agents for polymyalgia rheumatica treatment: assessing the critical needs for future development	19
Assessing the clinical potential of plozasiran, an APOC3 siRNA therapy for severe hypertriglyceridemia	18
Recent developments in adjunct therapies for type 1 diabetes	18
Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials	17
Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal	17
Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?	17
What is the progress of experimental drug development for fibromyalgia?	17
Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study	17
Treatment of anemia in myelofibrosis: focusing on novel therapeutic options	16
Investigational new drugs for the treatment of leishmaniasis	16
Current experimental and early investigational agents for cardiac fibrosis: where are we at?	16
Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration	16
Investigational regenerative medicine for non-traumatic osteonecrosis of the femoral head: a survey of registered clinical trials	16
The pleiotropic effects of glucagon-like peptide-1 receptor agonists in patients with metabolic dysfunction-associated steatohepatitis: a review for gastroenterologists	15
Targeting a key FAK-tor: the therapeutic potential of combining focal adhesion kinase (FAK) inhibitors and chemotherapy for chemoresistant non-small cell lung cancer	15
SOT201: cis -acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors	15
Frontotemporal dementia: from genetics to therapeutic approaches	15
Preclinical therapeutics for sickle cell disease: modern developments and future considerations	14
Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)	14
Investigative agents for atrial fibrillation: agonists and stimulants, progress and expectations	14
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents	14
Glucagon‑like peptide‑1 receptor agonists in multiple sclerosis: therapeutic promise, challenges, and future directions	14
NF1 alterations in cancers: therapeutic implications in precision medicine	14
Advancements in longevity pharmacology research – are we finally seeing clinical progression?	14
Pharmacokinetics and safety of dasatinib and its generic: a phase I bioequivalence study in healthy Chinese subjects	14
Navafenterol for chronic obstructive pulmonary disease therapy	13
Is seltorexant, an orexin-2 receptor antagonist, showing promise in insomnia?	13
Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis	13
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions	13
Experimental JAK inhibitors: the current, present, and future in graft-versus-host disease management?	13
Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 partici	13
MASLD and MASH: how a change of nomenclature may impact our approach in treating liver disease	13
Progress in the treatment of anal cancer: an overview of the latest investigational drugs	13
Investigational drugs for the treatment of olfactory dysfunction	13
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress	13
Assessing the clinical progress of the bispecific nanobody sonelokimab	13
First-in-human trial of SAR107375E, a novel small molecule anticoagulant with dual inhibition of factor Xa and factor IIa	13
Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents	12
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials	12
Immunotherapeutic strategies for treating opioid use disorder and overdose	12
Investigational agents for pancreatic neuroendocrine tumors: what clinical progress have we seen in the last 5 years?	12

Clinical development of tri-specific antibodies for immune-oncology	12
JAK inhibitors for rheumatoid arthritis	12
Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia	11
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosus	11
An update on novel investigational agents for the treatment of primary biliary cholangitis	11
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis	11
Investigational thrombolytic drugs for acute ischemic stroke	11
Zelenectide pevedotin (BT-8009): a bicyclic peptide toxin conjugate targeting nectin-4 for the treatment of bladder cancer	11
Investigational agents for ischaemic cardiomyopathy treatment: preclinical and early phase insights	11
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study	11
Investigational new drugs for the treatment of Dravet syndrome: an update	11
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies	10
Tafoxiparin effects on cervical ripening and labor augmentation	10
Bepirovirsen (GSK3228836) in chronic hepatitis B infection: an evaluation of phase II progress	10
Prospects of current AXL-targeting therapies in early phase cancer trials	10
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition	10
Pharmacological agents for bone fracture healing: talking points from recent clinical trials	10
IRAK signaling in cancers: mechanisms, targeting, and clinical implications	10
The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma	10
Inflammation and Huntington’s disease – a neglected therapeutic target?	10
A four-in-one first-in-human study to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and concentration-QTc relationship of HRS-1780, a selective non-steroidal mineralocorticoid recep	10
Investigational anti IL-13 asthma treatments: a 2023 update	10
Investigational drugs for the treatment of thymic cancer: a focus on phase 1 and 2 clinical trials	9
Investigational insights into the potential of angiotensin type II receptor agonists as therapeutics for idiopathic pulmonary fibrosis	9
Mantle cell lymphoma: what clinical progress in the last 5 years?	9
Approaches to combating methicillin-resistant Staphylococcus aureus (MRSA) biofilm infections	9
Evaluating phase II results of Baxdrostat, an aldosterone synthase inhibitor for hypertension	9
Assessing potential of psilocybin for depressive disorders	9
Menin inhibitors for adult acute myeloid leukemia: 2025 update	9
The impact of current investigational drugs for acne on future treatment strategies	9
The latest investigational drugs for patients with allergic rhinitis	9
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-c	8
Preclinical prospects of investigational agents for hearing loss treatment	8
Will new investigational drugs change the way we treat Charcot-Marie-Tooth disease?	8
The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs	8
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?	8
Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH	8
Islatravir: evaluation of clinical development for HIV and HBV	8
Investigational drugs in early phase trials for myelofibrosis	8
Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma	8
Psoriasis: talking points from recent clinical trials	8
Topical hypericin: a promising photodynamic therapy for early-stage cutaneous T-cell lymphoma	8
Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets	8
Retinal stroke: research models, targets and experimental drugs	8
Novel investigational drugs for alopecia areata and future perspectives	8
Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects	8
A VEGF gene therapy approach for the treatment of patients with coronary artery disease and refractory angina: assessment of clinical development	8
Novel agents to treat adrenal insufficiency: findings of preclinical and early clinical trials	8
Targeting inflammation in endometriosis: emerging therapeutic options	7
Insights into the anti-inflammatory and anti-arthritic potential of 3-Acetyl-11-keto-β-Boswellic Acid as a therapeutic approach in Rheumatoid Arthritis	7
Investigational DNA topoisomerase I inhibitors for colorectal cancer: preclinical and early phase developments	7
Trastuzumab-deruxtecan in solid tumors with HER2 alterations: from early phase development to the first agnostic approval of an antibody–drug conjugate	7
Investigational and emerging gastric inhibitory polypeptide (GIP) receptor-based therapies for the treatment of obesity	7
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies	7
Emerging pharmacotherapies for the treatment of pulmonary arterial hypertension	7
Bomedemstat as an investigative treatment for myeloproliferative neoplasms	7
Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease	7
Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review	7
Lonvoguran ziclumeran: a CRISPR-CAS9-based gene therapy for the treatment of hereditary angioedema	7
Novel preclinical developments of the primary sclerosing cholangitis treatment landscape	7
Triple negative breast cancer: what clinical progress have we seen in the last 5 years?	7
Experimental drugs for the prevention or treatment of sensorineural hearing loss	7
Fibroblast growth factor therapies in biliary tract cancers: current and future state	7
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials	7
Investigational drugs for the treatment of acromegaly: new agents to transform therapy	7
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study	7
Targeting aldosterone in sleep apnea: opening a new therapeutic era	7
Correction	7
T-cell acute lymphoblastic leukemia: promising experimental drugs in clinical development	7
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis	7
First-in-human phase I studies of YJ001 spray applied to local skin in healthy subjects and patients with diabetic neuropathic pain	6
Immune checkpoint inhibitors for the treatment of sepsis:insights from preclinical and clinical development	6
Investigational new drugs to treat brain metastasis from non-small cell lung cancer	6
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial	6
Gene expression inhibitors for the treatment of liver fibrosis: drugs under preclinical and early clinical investigation	6
Experimental drugs for Friedrich’s ataxia: progress and setbacks in clinical trials	6
Microbiome modulators for atopic eczema: a systematic review of experimental and investigational therapeutics	6
CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation	6
Clinical development of BPS804 for osteogenesis imperfecta: from failure to fruition?	6
Developments and challenges for new and emergent preparations for male hypogonadism treatment	6

Investigational drugs inhibiting complement for the treatment of geographic atrophy	6
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates	6
Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-2010, a novel anti-MASP-2 antibody, in healthy volunteers: a randomized, double-blind, placebo-controlled phase 1 study	6
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma	6
Zanzalintinib (XL092): a next-generation tyrosine kinase inhibitor—comprehensive review of early safety & efficacy data	6
A focused report on IFN-1 targeted therapies for lupus erythematosus	6
Pharmacokinetic equivalence and comparative safety, tolerability, and immunogenicity of Biocon’s ustekinumab (Bmab-1200) with EU-approved and US-licensed reference ustekinumab in healthy subjects: res	6
Pharmacokinetics, pharmacodynamics, safety, and immunogenicity of Gerilimzumab (GB224), a recombinant humanized interleukin-6 monoclonal antibody, in healthy Chinese adults: A randomized controlled do	6
Psoriasis: a focus on upcoming oral formulations	6
Retatrutide: a triple incretin receptor agonist for obesity management	6
Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?	6
Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study	6
Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline	5
Experimental and new investigational drugs for the treatment of uterine fibroids	5
Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis	5
Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date	5
Emerging therapies for overactive bladder: preclinical, phase I and phase II studies	5
Innovative therapies under clinical development for ALS treatment: small molecules	5
Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma	5
Current and emerging biological therapies for Chronic rhinosinusitis with nasal polyps with type 2 inflammation	5
New insights into the management of Behçet syndrome	5
Phosphodiesterase 5 inhibitors: preclinical and early-phase breakthroughs for impotence treatments	5
Tubulin polymerization inhibitors in early clinical studies as cancer therapeutics	5
Long COVID [post-acute sequelae of coronavirus disease 2019]: experimental drugs for cardiopulmonary complications	5
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights	5
Development of investigational radiotherapeutics for the diagnosis and treatment of glioma	5
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments	5
Targeting fatty acid synthase inhibitors for the treatment of acne vulgaris: what can we learn from early phase investigations	5
A phase 1, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of KN056 (a recombinant human GLP-1 variant Fc fusion prote	5
A randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and ammonia-lowering effect of Rifaquizinone, an intestinally restricted investigational drug	5
A comprehensive overview of investigational elastase inhibitors for the treatment of acute respiratory distress syndrome	5
Venetoclax in acute myeloid leukemia	4
Insulin sensitizers in 2023: lessons learned and new avenues for investigation	4
The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke	4
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases	4
Metabolic dysfunction and insulin sensitizers in acute and chronic disease	4
Investigational follicle-stimulating hormone receptor agonists for male infertility therapy	4
Investigational drugs for HIV: trends, opportunities and key players	4
Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy	4
Factor IX stimulants in preclinical and early phase trials for hemophilia B treatment	4
Novel carbonic anhydrase inhibitors for the treatment of Helicobacter pylori infection	4
Augmentation of natriuretic peptide (NP) receptor A and B (NPR-A and NPR-B) and cyclic guanosine monophosphate (cGMP) signalling as a therapeutic strategy in heart failure	4
KIF18A inhibition and its rising role in cancer therapy trials: from bench to bedside	4
Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review	4
Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia	4
Role of ROCK2 inhibitors in the treatment of chronic graft-versus-host disease	4
Avasopasem for the treatment of radiotherapy-induced severe oral mucositis	4
Istaroxime – update of data in early cardiogenic shock and decompensated heart failure	4
Early stage clinical trials for the treatment of hemophilia A	4
Design strategy and research progress of multifunctional nanoparticles in lung cancer therapy	4
Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions	4
Lipid metabolism and the targeting of angiopoietin-like 3: Experimental drugs under development	4
A randomized, double-blind, single dose, parallel group, 2-arm study assessing the pharmacokinetic similarity, pharmacodynamic, safety, tolerability, and immunogenicity profiles of biosimilar candidat	4
A phase I, randomized, double-blind, single-dose pharmacokinetic study to evaluate the biosimilarity of SB16 (proposed denosumab biosimilar) with reference denosumab in healthy male subjects	4
Polyvalent immunoglobulin therapy: preclinical evidence and potential for treating chemotherapy-induced peripheral neuropathy	4